• RESEARCH

    Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer

    Pooled analysis of 180 patients from the CAVE and CAVE-2 studies investigates clinical variables that predict response to cetuximab rechallenge (with or without avelumab) in patients with circulating tumor DNA RAS/BRAF/EGFR-extracellular domain wild-type metastatic colorectal cancer. (ESMO Gastrointestinal Oncology)